Search details
1.
Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.
N Engl J Med
; 390(17): 1549-1559, 2024 May 02.
Article
in English
| MEDLINE | ID: mdl-38669354
2.
Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali.
N Engl J Med
; 387(20): 1833-1842, 2022 Nov 17.
Article
in English
| MEDLINE | ID: mdl-36317783
3.
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
N Engl J Med
; 387(5): 397-407, 2022 08 04.
Article
in English
| MEDLINE | ID: mdl-35921449
4.
A Monoclonal Antibody for Malaria Prevention.
N Engl J Med
; 385(9): 803-814, 2021 08 26.
Article
in English
| MEDLINE | ID: mdl-34379916
5.
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.
J Infect Dis
; 226(3): 510-520, 2022 08 26.
Article
in English
| MEDLINE | ID: mdl-35134995
6.
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Lancet
; 393(10174): 889-898, 2019 03 02.
Article
in English
| MEDLINE | ID: mdl-30686586
7.
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
JAMA
; 323(14): 1369-1377, 2020 04 14.
Article
in English
| MEDLINE | ID: mdl-32286643
8.
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
PLoS Med
; 15(1): e1002493, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29364886
9.
Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.
J Virol
; 90(13): 5899-5914, 2016 07 01.
Article
in English
| MEDLINE | ID: mdl-27053554
10.
Mosaic quadrivalent influenza vaccine single nanoparticle characterization.
Sci Rep
; 14(1): 4534, 2024 02 24.
Article
in English
| MEDLINE | ID: mdl-38402303
11.
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.
JCI Insight
; 9(7)2024 Apr 08.
Article
in English
| MEDLINE | ID: mdl-38587079
12.
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.
Lancet HIV
; 10(4): e230-e243, 2023 04.
Article
in English
| MEDLINE | ID: mdl-37001964
13.
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
BMJ Open
; 13(8): e076843, 2023 08 28.
Article
in English
| MEDLINE | ID: mdl-37640457
14.
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.
MAbs
; 15(1): 2165390, 2023.
Article
in English
| MEDLINE | ID: mdl-36729903
15.
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
Sci Transl Med
; 15(692): eade4790, 2023 04 19.
Article
in English
| MEDLINE | ID: mdl-37075129
16.
Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development.
Biotechnol Prog
; 38(6): e3296, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36054677
17.
Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency.
Sci Rep
; 12(1): 8433, 2022 05 19.
Article
in English
| MEDLINE | ID: mdl-35589938
18.
Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life.
Sci Rep
; 12(1): 17876, 2022 10 25.
Article
in English
| MEDLINE | ID: mdl-36284200
19.
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Lancet Infect Dis
; 22(8): 1210-1220, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35568049
20.
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
Nat Med
; 28(2): 383-391, 2022 02.
Article
in English
| MEDLINE | ID: mdl-35115706